Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by 2027. See why BLUE stock is a Hold.

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

bluebird's Board of Directors (the “bluebird ... analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Bluebird Bio (NASDAQ: BLUE) said its planned acquisition by two investment firms is, according to its board, “in the best interest of stockholders”—but enough of them felt otherwise on ...

bluebird stockholders to receive $3.00 per share ... analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Philip Gregory, chief scientific officer at bluebird, said the latest analysis showed that the integration site of the vector was in a gene called VAMP4. bluebird bio's Philip Gregory VAMP4 has no ...

Bluebird has said it hopes to have some data within the next few weeks that should explore the possibility of a causal link. That is concentrating on determining where the vector integrated into ...

Both heavy-hitting photo editing apps come from Adobe, but which one is right for your needs—or should you use both? Here's how Photoshop and Lightroom stack up on price, features, and more.

Given the recent M&A activity associated with companies such as 2seventy Bio, and BlueBird, and considering Precision Biosciences low market cap ($40 million), I wouldn’t be surprised if the ...